Literature DB >> 1582975

Mechanisms of bone lesions in multiple myeloma.

R Bataille1, D Chappard, B Klein.   

Abstract

Lytic bone lesions and hypercalcemia are common features of multiple myeloma; however, they are exceptional in other B-cell malignancies. Myeloma bone involvement is related to an uncoupling process associating an increased osteoclastic resorption with decreased bone formation. Several osteoclast-activating factors such as interleukin-1 (IL-1), tumor necrosis factor, and interleukin-6 (IL-6) are involved in this process. IL-6, the major myeloma cell growth factor, could play a critical role in myeloma-induced bone resorption in association with other known or unknown hematopoietic growth factors, however.

Entities:  

Mesh:

Year:  1992        PMID: 1582975

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  10 in total

Review 1.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.

Authors:  P K Pattengale
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

3.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Authors:  R N Pearse; E M Sordillo; S Yaccoby; B R Wong; D F Liau; N Colman; J Michaeli; J Epstein; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

4.  Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.

Authors:  M Laroche; M Attal; C Dromer
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

Review 5.  Mechanisms involved in the metastasis of cancer to bone.

Authors:  F W Orr; P Kostenuik; O H Sanchez-Sweatman; G Singh
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 6.  Cancer-associated bone disease.

Authors:  R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-10-22       Impact factor: 4.507

7.  Quantification of dendritic cells and osteoclasts in the bone marrow of patients with monoclonal gammopathy.

Authors:  Nicolas Josselin; Hélène Libouban; Mamoun Dib; Norbert Ifrah; Erick Legrand; Michel Félix Baslé; Maurice Audran; Daniel Chappard
Journal:  Pathol Oncol Res       Date:  2008-08-28       Impact factor: 3.201

Review 8.  Interleukin-6, a new target for therapy in multiple myeloma?

Authors:  M H van Oers; H C van Zaanen; H M Lokhorst
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

9.  Altered mental status and low anion gap in a patient with sickle cell anemia: a case report.

Authors:  Siddharth A Wartak; Reshma A Mehendale; Benjamin Freda; Ashish Verma; David N Rose
Journal:  J Med Case Rep       Date:  2012-02-20

10.  Young patient with arterial thrombosis and skin changes as the onset manifestations: POEMS syndrome.

Authors:  Ting-Ting Han; Shuang Zheng; Zeng-Ai Chen; Wei Liu; Yao-Min Hu
Journal:  Oncotarget       Date:  2016-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.